Urinary Iodine-to-Creatinine Ratio and Outcomes After Radioactive Iodine Ablation in Thyroid Cancer
Open Access
- 3 June 2026
- journal article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (8)
Abstract
Context: Radioactive iodine ablation (RAIA) in differentiated thyroid cancer (DTC) requires elevated TSH levels, achieved through thyroid hormone withdrawal (THW) or recombinant human TSH (rhTSH). A low-iodine diet (LID) is recommended to enhance RAIA efficacy, but its impact on long-term outcomes remains uncertain. Objective: To determine whether pre-ablation urinary iodine concentrations predict disease outcomes after RAIA. Study design: Retrospective study of DTC patients treated with post-surgical RAIA at BIDMC from 2007-2020 Patients: Of 463 patients reviewed, 304 met inclusion criteria (THW:189; rhTSH:115). All completed a 2-week LID. Urinary iodine-to-creatinine ratio (UICR) was measured as a marker of iodine status. Main Outcome Measure(s): Disease recurrence at 12 months, defined by elevated thyroglobulin (Tg), abnormal neck ultrasound, or a positive whole-body scan. Associations between UICR and outcomes were evaluated using univariable and multivariable logistic regression. Results: Positive pre-treatment Tg (OR 6.13, 95% CI 1.90–19.83; p=0.002) and AJCC stage IV disease (OR 8.45, 95% CI 1.39–51.36; p=0.02) were independently associated with recurrence. Older age was associated with lower recurrence risk only in unadjusted models. UICR showed no association with outcomes. Although mean UICR was higher in the rhTSH group (p<0.0001), recurrence rates were similar between THW and rhTSH (p=0.3). Conclusions: Higher UICR in rhTSH-prepared patients did not translate into worse outcomes. Pre-treatment Tg and stage IV disease were the strongest predictors of recurrence, whereas iodine status was not. These findings suggest that strict iodine depletion at the level achieved here, reflected by UICR, may not determine RAIA efficacy in DTC.Keywords
Funding Information
- Norges Idrettshøgskole (F32-DK126432)
- Joslin Diabetes Center
This publication has 14 references indexed in Scilit:
- Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for 131I Therapy in Patients With Intermediate- to High-Risk Thyroid CancerClinical Nuclear Medicine, 2024
- Influence of Levothyroxine With Recombinant Human Thyroid-Stimulating Hormone on Urinary Iodine Excretion Before Radioactive Iodine AdministrationEndocrine Practice, 2021
- A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinomaOral Oncology, 2018
- Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancerAnnals of Nuclear Medicine, 2018
- Low iodine diet in differentiated thyroid cancer: a reviewClinical Endocrinology, 2015
- The Results of Selective Use of Radioactive Iodine on Survival and on Recurrence in the Management of Papillary Thyroid Cancer, Based on Memorial Sloan-Kettering Cancer Center Risk Group StratificationThyroid®, 2013
- Association Between Excessive Urinary Iodine Excretion and Failure of Radioactive Iodine Thyroid Ablation in Patients with Papillary Thyroid CancerThyroid®, 2013
- Dietary Iodine Restriction in Preparation for Radioactive Iodine Treatment or Scanning in Well-Differentiated Thyroid Cancer: A Systematic ReviewThyroid®, 2010
- Usefulness of iodine/creatinine ratio from spot‐urine samples to evaluate the effectiveness of low‐iodine diet preparation for radioiodine therapyClinical Endocrinology, 2010
- Effects of low‐iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinomaClinical Endocrinology, 2003